Shares of Intrexon Corporation (NYSE:XON) advanced to $25.27. The price had gained 0.56% or 0.14 points intraday. The latest trading session witnessed $9.89 million in upticks and $11.1 million in downticks, resulting in net money flow of (-1.21) million. The up/down ratio for the day stood at 0.89. On a weekly scale, the price has seen a change of -12.74%. From the trading data available, it was disclosed that a block trade of negative money flow worth $(0.5) million occurred during the day. $0.5 million in uptick and $0 million in downtick were the highlight of the block transaction which had an up/down ratio of 0.
Currently the company Insiders own 59.6% of Intrexon Corporation shares according to the proxy statements. Institutional Investors own 85.26% of Intrexon Corporation shares. On the companys insider trading activities, Kirk Randal J, CEO of Intrexon Corp, had purchased 124,475 shares on December 11, 2015. The total value of the transaction was $3,714,334. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.
Intrexon Corporation (NYSE:XON) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.14 points or 0.55% at $25.13 with 1,444,340 shares getting traded. Post opening the session at $25, the shares hit an intraday low of $25 and an intraday high of $26.7 and the price was in this range throughout the day. The company has a market cap of $2,969 million and the number of outstanding shares have been calculated to be 118,164,614 shares. The 52-week high of Intrexon Corporation (NYSE:XON) is $69.45 and the 52-week low is $18.5201.
Many analysts have stated their opinion on the company shares. JMP Securities initiates coverage on Intrexon Corporation (NYSE:XON) The current rating of the shares is Market Outperform. The rating by the firm was issued on May 3, 2016.
Intrexon Corporation is engaged in the field of synthetic biology. The Company designs, builds and regulates gene programs, which are Deoxyribonucleic Acid (DNA) sequences that consist of genetic components. The Companys synthetic biology capabilities include the ability to control the amount, location and modification of biological molecules to control the function and output of living cells. The Companys technologies include UltraVector, RheoSwitch Therapeutic System, Cell Systems Informatics, Protein Engineering, AttSite Recombinases, LEAP (Laser Enabled Analysis and Processing), Antibody Discovery, Neurospora & Agaricus Platforms, Endometrial Regenerative Cells, ActoBiotics, Porcine Research Models and BeyondBio. The Company serves various markets, including health, food, energy, environment and consumer. The Company has five operating divisions: Human Therapeutics, Synthetic Immunology, Animal Sciences, Agricultural Biotech, and Industrial Products.